Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 558.46M | 412.00M | 314.05M | 284.44M | 213.53M |
Gross Profit | 327.22M | 251.34M | 212.74M | 200.73M | 156.24M |
EBITDA | 121.35M | 262.86M | 144.56M | 76.61M | 110.37M |
Net Income | 315.15M | 242.30M | 117.32M | 40.62M | 85.20M |
Balance Sheet | |||||
Total Assets | 5.11B | 4.89B | 4.60B | 4.12B | 227.06M |
Cash, Cash Equivalents and Short-Term Investments | 4.15B | 4.40B | 4.22B | 3.91B | 147.09M |
Total Debt | 22.63M | 8.19M | 11.26M | 13.17M | 12.07M |
Total Liabilities | 253.56M | 248.61M | 171.31M | 143.37M | 75.64M |
Stockholders Equity | 4.80B | 4.60B | 4.40B | 3.95B | 151.41M |
Cash Flow | |||||
Free Cash Flow | 87.44M | 69.34M | 69.70M | 42.47M | 110.42M |
Operating Cash Flow | 108.32M | 101.87M | 77.19M | 44.43M | 111.05M |
Investing Cash Flow | 111.02M | -634.95M | -3.59B | -50.54M | 13.00K |
Financing Cash Flow | -197.89M | -133.13M | -22.38M | 3.79B | -2.83M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | HK$3.24B | 10.59 | 7.40% | 4.59% | 0.67% | -1.75% | |
78 Outperform | HK$57.88B | 7.58 | 9.19% | 3.98% | -3.94% | -23.48% | |
75 Outperform | HK$10.48B | 30.51 | 6.72% | 2.08% | 33.41% | 26.81% | |
66 Neutral | $65.29B | 9.36 | 6.08% | 2.95% | 3.27% | 12.87% | |
60 Neutral | HK$15.31B | 5.72 | -7.43% | 4.61% | 11.60% | -21.06% | |
45 Neutral | HK$701.35M | ― | -31.49% | ― | -7.28% | -46.18% |
Medlive Technology Co., Ltd. has updated the terms of reference for its Nomination Committee, effective from June 30, 2025. The committee, which will consist of at least three directors with a majority being independent non-executive directors, is tasked with reviewing the board’s structure and composition annually. This move aims to ensure the board’s alignment with the company’s corporate strategy and enhance its governance by selecting qualified individuals for directorships.
Medlive Technology Co., Ltd. held its Annual General Meeting on May 8, 2025, where all proposed resolutions were approved by shareholders. Key outcomes included the re-election of directors, the declaration of a final dividend for 2024, and the approval of mandates for share repurchase and issuance, indicating strong shareholder support and strategic direction for the company’s future operations.
Medlive Technology Co., Ltd. has announced its upcoming annual general meeting scheduled for May 8, 2025, where key resolutions will be considered. These include the approval of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks shareholder approval for share repurchase and issuance mandates, potentially impacting its capital structure and market operations.